TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.

Bruno Sangro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.